Form 4: Heron Therapeutics Executive Acquires Shares Through RSU Vesting

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, acquired 12,500 shares of common stock through the vesting of restricted stock units.

Summary

• William P. Forbes, the Executive Vice President and Chief Development Officer of Heron Therapeutics, Inc. (HRTX), acquired 12,500 shares of the company's common stock.
• This acquisition occurred on June 6, 2025, and resulted from the vesting and conversion of previously granted restricted stock units (RSUs).
• Following this transaction, Mr. Forbes' direct beneficial ownership of common stock increased to 135,066 shares.
• He continues to hold 25,000 unvested restricted stock units, which are subject to a vesting schedule of four equal annual installments beginning one year after the grant date, contingent on his continued service to the Issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a routine compensation event, indicating continued executive alignment with shareholder interests, but does not convey new operational or financial performance information.

Positives

• The acquisition of shares through RSU vesting demonstrates continued equity ownership by a key executive, aligning their interests with those of shareholders.
• The vesting schedule encourages long-term commitment and retention of the executive within the company.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, where equity awards like Restricted Stock Units are a standard component of remuneration packages designed to align management incentives with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation, with a multi-year vesting schedule, is a standard practice across the pharmaceutical and biotechnology industries, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Biogen, which also utilize equity awards to incentivize long-term performance and retention of key personnel.

Stakeholder Impact

• Shareholders: The transaction increases the executive's direct ownership in the company, which generally aligns management's interests with those of shareholders.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Future vesting of the remaining 25,000 restricted stock units held by William P. Forbes, subject to his continued service to Heron Therapeutics.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, William P. Forbes, Stock Acquisition